Menu
Oslo, Norway, 20 December 2024: Reference is made to stock exchange announcements by Thor Medical ASA (the "Company") on 12 December 2024 regarding the completion of a private placement of a total of 63,000,000 new shares (the "Offer Shares") in the Company raising a total of NOK 157.5 million (the "Private Placement") and a retail offering of a total of 6,029,300 new shares (the "PrimaryBid Shares") raising a total of approx. NOK 15 million (the "PrimaryBid Offering").
The share capital increase relating to tranche 1 of the Private Placement ("Tranche 1"), consisting of 39,603,620 Offer Shares, and the share capital increase relating to the PrimaryBid Offering, consisting of 6,029,300 PrimaryBid Shares, is now registered with the Norwegian Register of Business Enterprises. The Company's share capital is after the registration NOK 56,098,479 divided into 280,492,395 shares. Each share has a nominal value of NOK 0.20 and represents one vote in the Company's general meeting.
The second tranche consists of 23,396,380 Offer Shares ("Tranche 2"). The settlement of Offer Shares in Tranche 2 is expected to take place on or about 8 January 2025, subject to a resolution by the general meeting, scheduled to be held on 6 January 2025. For further information on Tranche 2, reference is made to the stock exchange announcement on 12 December 2024.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
CONTACTS
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
